ESR1 and breast carcinoma: Due to its affordability and high efficacy [2], as shown in a reduction of breast cancer recurrence by around 30% in the first 15 years of therapy, the selective estrogen receptor modulator tamoxifen is widely used in premenopausal and postmenopausal breast cancer patients [3,4].